目录:MedChemExpress LLC>>生化试剂>> Irinotecan | MCE
CAS | 97682-44-5 | 纯度 | 99.84% |
---|---|---|---|
分子量 | 586.68 | 分子式 | C₃₃H₃₈N₄O₆ |
供货周期 | 现货 | 规格 | 50 mg |
货号 | HY-16562 | 应用领域 | 医疗卫生,化工,生物产业,制药/生物制药 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 97682-44-5
产品活性:Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.
研究领域:Cell Cycle/DNA Damage | Autophagy
作用靶点:Topoisomerase | Autophagy
In Vitro: Irinotecan is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM.
In Vivo: Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | CNS-Penetrant Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Lung Cancer Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Children’s Drug Library | Chemotherapy Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Heterocyclic Compound Library | Off-patent Drug Library | Gepotidacin | Topoisomerase IV inhibitor 2 | Phenoxodiol | Topotecan hydrochloride hydrate | NHC-triphosphate tetraammonium | Berberine | Levofloxacin sodium | TAS-103 dihydrochloride | Ciprofloxacin | Mitoxantrone diacetate | Murrayanol | Gimatecan | Camptothecin | EGFR-IN-57 | SW044248 | Topoisomerase I/II inhibitor 4 | NHC-diphosphate triammonium | Betulinic acid | 3,6-Diamino-9(10H)-acridone | Epirubicin | 12-Ethyl-9-hydroxycamptothecin | Topoisomerase II inhibitor 3 | Becatecarin | Pixantrone hydrochloride | Datopotamab deruxtecan | Isosteviol | 9-Hydroxyellipticine hydrochloride
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种*仅有化合物库,我们致力于为*科研客户提供前沿的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药 Patent 收录了MCE客户的科研成果;
• 专业团队跟踪新的制药及生命科学研究进展,为您提供*新的活性化合物;
• 与世界各大制药公司及*科研机构建立了长期的合作。